A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...
This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approvedMILAN--(BUSINESS WIRE)--#CGT--With the decision by ...
Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...
The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...
Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited ...
The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States ...
The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback